sPD-1蛋白治疗小鼠H22肝癌的实验研究

Experimental Research on sPD-1 Protein in the Treatment of Mice Bearing H22 Liver Cancer

目的:观察sPD-1蛋白对小鼠H22肝癌腹水瘤生长的抑制作用。方法:建立H22肝癌小鼠腹水瘤模型,将24只接种H22肝癌细胞BALB/c小鼠随机分成3组,其腹腔分别注射PBS(模型组)、DDP(阳性对照组)以及sPD-1蛋白,用药15 d后,停止用药,取腹水测定腹水细胞Treg细胞的产生情况,并观察小鼠的毒副反应以及生存期。结果:sPD-1蛋白组的H22肝癌生命延长为(25.75±4.30)d,DDP组的H22肝癌生命延长为(25.00±4.41)d,均明显高于对照组的(16.63±2.67)d(P<0.05)。sPD-1蛋白组小鼠腹水中Treg细胞明显少于DDP组和模型组,免疫水平优于DDP和PBS组。结论:原核表达的sPD-1蛋白对小鼠H22肝癌腹水瘤的生长具有明显抑制作用,并能促进机体免疫系统功能,提高生存期。

Objective： To research the inhibitory effect of sPD-1 protein on H22 liver cancer in mice. Methods： The mouse hepatoma H22 cells were injected intraperitoneally into the BALB/c mice to establish H22-bearing mice model, and all the 24 mice H22-bearing mice were randomized into three groups according to different treatment： PBS group （model group）, DDP group （positive control）, and sPD-1 protein group. After 15 days＇ treatment, ascites samples were taken out from the tumor bearing mice for Treg cells detection, and survival days were compared. Results： The life prolonged days in sPD-1 group （25.75±4.30） and DDP （25.00±4.41） group were significantly longer than that in control group （16.63±2.67） （P〈0.05）. Compared with that in DDP group and model group, Treg cells in ascites of sPD-1 protein group were significantly less. Conclusion： sPD-1 protein has an anticancer effect on H22 liver cancer in mice, and can promote the immune function and prolong the survival time.